基底动脉封闭的内血管治疗:重新审视随机临床试验的证据
Sherief Ghozy1,2, Amr Ehab El-Qushayri3, Mohamed Elfil4
1Department of Radiology Mayo Clinic Rochester MN.
Stroke (Hoboken, N.J.)
|January 29, 2026
概括
内血管治疗 (EVT) 改善了由基底动脉封闭引起的急性缺血性中风的结果,降低了死亡率. 然而,EVT也增加了症状性脑内出血的风险,需要进一步调查.
科学领域:
- 神经学 神经学
- 干预心脏病学 干预心脏病学
- 血管外科 血管外科
背景情况:
- 基底动脉封闭导致严重的缺血性中风,死亡率和残疾率高.
- 之前的试验缺乏证据证明内血管治疗 (EVT) 在基底动脉封闭中的有效性.
- 最近的试验如ATTENTION和BAOCHE提供了关于EVT的最新数据.
研究的目的:
- 评估EVT对急性缺血性中风的益处和安全性,原因是基底动脉封闭.
- 综合关键临床试验的最新证据.
- 提供对EVT在管理这种情况中的作用的最新见解.
主要方法:
- 在2022年11月1日之前,对5个数据库进行系统搜索.
- 包括所有随机对照试验,无论出版日期或语言.
- 使用R软件 (4.2.1版本) 进行的元分析.
主要成果:
- EVT显著提高了0-3 (RR,1.54) 和0-2 (RR,1.83) 修改的兰金评分的比率.
- EVT导致90天死亡率显著降低 (RR,0.76).
- EVT与显著更高的症状性脑内出血率相关 (RR,7.48).
结论:
- 在急性缺血性中风患者中,EVT可能为患有基底动脉封闭的患者提供临床益处.
- 这些发现的概括性可能是有限的,因为研究数量很少,而且研究重点是中国人口.
- 需要进一步的试验来确认这些结果并探索更广泛的适用性.
更多相关视频
相关概念视频
Clinical Trials
10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview
4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
The Evidence for Evolution
48.0K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
48.0K
Statistical Software for Data Analysis and Clinical Trials
1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Coronary Artery Disease III: Clinical Manifestations
368
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
368
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
596
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
596


